Posts filtered by tags: Eli Lilly Co[x]


Experimental Antibody Treatment for Covid-19 Patients Wins 'Emergency Approval' in America

America's Food and Drug Administration granted emergency authorization Saturday to an experimental antibody treatment (for people already experiencing Covid-19), reports the Washington Post: The drug, made by Regeneron Pharmaceuticals, is designed to prevent infected people from developing severe illness. Instead of waiting for the body to develop its own protective immune response, the drug imitates the body's natural defenses. It is the second drug of this type — called a monoclonal antibody ...
Tags: Washington, America, Tech, Fda, New England Journal of Medicine, Lilly, Regeneron, Regeneron Pharmaceuticals, Eli Lilly Co, COVID, America s Food and Drug Administration

Eli Lilly's Covid-19 Antibody Drug Just Received Emergency FDA Clearance

A drug proven to help prevent hospitalizations in high-risk patients already sick with Covid-19 will soon become widely available, thanks to an emergency FDA clearance issued Monday night for an Eli Lilly & Co.-manufactured antibody therapy.Read more...
Tags: Science, Fda, Antibody, Eli Lilly, Eli Lilly Co, Covid 19, COVID

FDA reportedly found quality-control lapses at Eli Lilly plant making COVID-19 drug

The feds found serious quality-control lapses at a New Jersey factory where Eli Lilly & Co. plans to produce its antibody treatment for...
Tags: New Jersey, Fda, Eli Lilly, Eli Lilly Co

Evi Sachenbacher: Sacrificial Lamb on the Doping Altar

Germany’s Evi Sachenbacher-Stehle (bib-27) in the quaterfinals of the 2007 Tour de Ski in Prague. (Photo: Wikimedia Commons)   A career ended prematurely, for no reason. During the 2014 Winter Olympics in Sochi, Russia, German biathlete Evi Sachenbacher failed a doping test. Although the ensuing ban was subsequently reduced from two years to six months, it effectively ended her career. New information seems to confirm that Sachenbacher’s positive drugs test at the 2014 Winter Olympics in S...
Tags: News, Germany, Russia, Sport, Prague, Daily Mail, United States, Skiing, New York Times, Sochi, Wada, Doping, Munich Germany, Court of Arbitration for Sport, CAS, World Anti Doping Agency Wada

Eli Lilly testing whether novel COVID-19 antibody drug can quash outbreaks in nursing homes

Eli Lilly & Co. has started a Phase 3 trial of its experimental antibody-based COVID-19 drug in nursing homes and other long-term care facilities, testing whether the drug reduces the infection rate at facilities where residents or staff have recently tested positive for the new coronavirus. The study involves Eli Lilly driving specially modified RVs to newly infected nursing homes and injecting its COVID-19 drug, code-named LY-CoV555, in volunteers, The Wall Street Journal reports. The company ...
Tags: News, Obama, Wall Street Journal, Trump, Eli Lilly, Eli Lilly Co, COVID, AbCellera Biologics

Trump Calls HHS Chief Azar After Reports Cast Him as Imperiled

(Bloomberg) -- President Donald Trump called Health and Human Services Secretary Alex Azar this weekend to say his job is safe after reports the White House may oust the health chief as the administration faces criticism over its coronavirus response.The call, described by a person familiar with the matter, and a Trump tweet on Sunday backing Azar came after multiple news accounts saying some officials within the White House had discussed his dismissal and potential replacements. Azar also weigh...
Tags: Politics, News, White House, Bloomberg, Cnn, Canada, New York Times, Times, Donald Trump, Alex, Wall Street Journal, Journal, Trump, Reuters, Health And Human Services, Mike Pence

Eli Lilly to delay new studies as coronavirus puts strain on hospitals

U.S. drugmaker Eli Lilly & Co said on Monday it would delay starting new studies and pause enrolment in ongoing studies, as it looks to free up healthcare facilities and doctors to attend to the growing number of COVID-19 patients.
Tags: Money, businessNews, Eli Lilly, Eli Lilly Co, COVID

Teva stops testing its migraine drug as cluster headache treatment

The drug, known generically as fremanezumab, competes with rival treatments from Eli Lilly & Co and Amgen Inc. Lilly in November received the U.S. Food and Drug Administration's "breakthrough" status for its migraine drug Emgality in treating episodic cluster headaches. In a late-stage trial, three out of four patients treated with Lilly's drug saw at least a 50 percent reduction in weekly cluster headaches. Teva's decision could be positive for Lilly's drug in differentiating it from its riv...
Tags: News, U S Food and Drug Administration, BMO Capital Markets, Lilly, Teva, Eli Lilly Co, Alex Arfaei, Amgen Inc Lilly

Sanofi to cut U.S. insulin costs for some patients to $99 per month

Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers - Eli Lilly & ...
Tags: Science, United States, Novo Nordisk, Sanofi, Sanofi SA, Eli Lilly Co

Eli Lilly offers half-price, generic insulin in counter to drug cost pressure

Drugmaker Eli Lilly & Co. will offer a half-priced version of its blockbuster insulin, becoming one of the first companies to effectively cut the price of a top-selling drug amid the ongoing U.S. debate over pharmaceutical costs. While it will continue selling its brand-name version at the existing price, Indianapolis-based Lilly will also sell a half-cost “authorized generic” for $137.35 a vial, or $265.20 for a five-pack of injectable pens. That will give a better deal to customers who pay cas...
Tags: Business, Congress, Washington, Senate, Sport, Indianapolis, Soccer, Medicare, Novo Nordisk, Lilly, Sanofi, Mylan NV, Eli Lilly, Eli Lilly Co, David Ricks, Olivier Brandicourt

No Sovereign Immunity for Patent-Asserting State University

by Dennis Crouch University of Florida Research Foundation, Inc. v. General Electric Company (Fed. Cir. 2019) UF’s asserted patent is titled “Managing Critical Care Physiologic Data Using Data Synthesis Technology.” U.S. Patent No. 7,062,251.  From the patent title, keen Patently-O readers will recognize a potential eligibility problem.  N.D.Fla. District Court Judge Mark Walker dismissed the case on a R.12(b)(6) motion without taking any evidence — finding the asserted claims ineligible as a ma...
Tags: Florida, Ge, Supreme Court, Law, United States, Patent, Citizens, Alice, Fed, UF, Knight, Federal Circuit, IPR, Mark Walker, Eli Lilly Co, Versata

Patent File Wrapper Estoppel Comes to Canada

In a move that surprised many in the IP community, a budget bill that received royal assent before the holidays, introduced file wrapper estoppel to Canadian patent law. Bill C-86 (link) included a number of changes to intellectual property legislation including enacting the College of Patent Agents and Trade-mark Agents Act, reforming the Copyright Board, and numerous amendments to the Patent Act, Trade-marks Act and Copyright Act. One of the changes to the Patent Act, allows for the patent fil...
Tags: UK, Supreme Court, Law, US, Canada, United States, Intellectual Property, US supreme court, Patent Office, Locke, SG, Eli Lilly Co, Neuberger, Pollard Banknote Limited, Babn Technologies Corp, Copyright Board

Shutdown creates uncertainty over Uber and Lyft IPO timing

Uber and Lyft are still waiting for feedback from the U.S. securities regulator on their confidential submissions for IPOs, Bloomberg reports tonight, citing people familiar with the matter who aren't disclosing their identities. Donald Trump’s government shutdown over his demand for a wall on the U.S.-Mexico border has effectively halted all but basic operations at the Securities and Exchange Commission. No SEC means no IPOs. From Bloomberg, on how this impacts the Uber and Lyft IPO plans: ...
Tags: Lyft, Uber, Post, Business, Technology, News, Mexico, San Francisco, Bloomberg, SEC, Donald Trump, Shutdown, Securities And Exchange Commission, Trump, Uber and Lyft, Eli Lilly Co

Lilly partners with AC Immune for Alzheimer's treatment

Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease.
Tags: Money, businessNews, Lilly, Eli Lilly Co, AC Immune, AC Immune SA

Alphabet and Simon Property skid while Constellation rises

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:Constellation Brands Inc., up $11.34 to $222.10The beer, wine and liquor maker raised its profit forecast for the year.Eli Lilly & Co., up $4.37 to $112.99The... [Author: [email protected]]
Tags: Business, New York, Ap, Constellation Brands Inc, Eli Lilly Co

Layers of Doctrine with a Faulty Claim Construction at the Core

by Dennis Crouch D Three Enterprises v. SunModo Corp. (Fed. Cir. 2018) Reading this decision feels akin to slowly peeling off the layers of an onion – hoping to reach some prize at the core but only reaching a rotten core. D-Three’s patents in suit are directed to roof-mount sealing assemblies for solar panel installation.  U.S. Patent Nos. 8,689,517; 9,068,339; and 8,707,655.   The district court found the asserted claims invalid as obvious or anticipated.  The basic central dispute, however, w...
Tags: Law, Patent, Fed, Federal Circuit, Lockwood, Dennis Crouch, Eli Lilly Co, PHOSITA, Ariad Pharm Inc, D Three Enterprises, SunModo Corp Fed, Am Airlines Inc, Gentry Gallery LizardTech

Eli Lilly’s animal health business draws PE interest: Bloomberg

Bain Capital and Advent International are interested in Eli Lilly & Co’s animal health business, Bloomberg is reporting. Carlyle is also considering making a proposal for Elanco, the story said. Elanco could be valued at $14 billion to $16 billion, Bloomberg said.
Tags: Trends, Bloomberg, Bain Capital, Carlyle, Eli Lilly, Elanco, Eli Lilly Co, PE Deals

For Predictable Arts: Written Description of Genus Satisfied by Single Species Disclosure and Fact that Other Members of Genus are Well Known in the Art

by Dennis Crouch 35 U.S.C. 112(a) requires that a patent specification include a “written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms.”  That statutory language serves as the basis for the written description requirement — whose purpose is to ensure that “the inventor actually invented the invention claimed.” Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc). Claims that were not s...
Tags: Law, Patent, Fed, Board, Newman, Emanuel, Federal Circuit, ARIAD, Stoll, Hologic, Dennis Crouch, Eli Lilly Co, Smith Nephew, PHOSITA, Ariad Pharm Inc, PTAB Board

Former Drug Industry Executive Will Lead Dept. Of Health And Human Services

Alex Azar spent five years in charge of Eli Lilly & Co.'s U.S. operations. During his tenure, the prices for the company's insulin products more than doubled.(Image credit: Carolyn Kaster/AP)
Tags: News, Eli Lilly Co, Alex Azar

Patent Games Cannot Save Blockbuster Remicade Patent

In re Janssen and NYU  (Johnson & Johnson) (Fed. Cir. 2018). In an ex parte reexamination of U.S. Patent No. 6,284,471, the Patent Trial and Appeal Board affirmed the examiner’s conclusions that NYU’s claims unpatentable under the judicial doctrine of obviousness-type double patenting. NYU and J&J have played a few games with this particular patent family of 30+ patents.  The claims relate to antibodies and assay methods associated with a tumor necrosis factor (TNF) and is said to cover J&J’s bl...
Tags: Law, Patent, Nyu, Fed, Amgen, CIP, Pfizer Inc, Federal Circuit, Searle, Janssen, Patent Trial and Appeal Board, Eli Lilly Co, GATT, Teva Pharm USA Inc, NYU Johnson Johnson Fed, Searle LLC

United States: Eli Lilly's Pemetrexed Therapy Claims Survive Challenge At PTAB - Marshall, Gerstein & Borun LLP

The Federal Circuit's decision in Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 845 F.3d 1357 (Fed. Cir. 2017) attracted much attention for applying the theory of divided infringement in the context of pharmaceutical therapeutic regimen claims.
Tags: News, United States, Fed, Federal Circuit, Eli Lilly, Eli Lilly Co, Teva Parenteral Medicines Inc, Gerstein, Borun LLP

Does the Federal Circuit's In re Cray Decision Suggest a New Business Model for Savvy Infringers?

By Kevin E. Noonan -- Patent law has always been tasked with interpreting law in an ever-shifting factual environment, where well-established principles need to be applied to new technology. Twenty years ago, the Federal Circuit grappled with the application of the written description requirement to biotechnology inventions, in seminal cases beginning with Regents of the University of California v. Eli Lilly & Co. (1996), and culminating in Ariad v. Eli Lilly (2010) (en banc). More recently (and...
Tags: Supreme Court, Law, University Of California, Federal Circuit, ARIAD, Eli Lilly, Eli Lilly Co, Patent Docs, Kevin E Noonan

RH and Mastercard rise while XL Group, Barnes & Noble drop

NEW YORK (AP) " Stocks that moved substantially or traded heavily Thursday:RH, up $22.12 to $71.54The furniture and housewares retailer raised its annual forecasts after a strong second-quarter report.Eli Lilly & Co., up $1.03... [Author: [email protected]]
Tags: Business, New York, Mastercard, Eli Lilly Co, XL Group Barnes amp

CORRECTED: Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial

Eli Lilly & Co. said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial.
Tags: Finance, Article, FBN, Eli Lilly Co, Fbn/markets, MarketWatch Pulse, FOX BUSINESS/MARKETS, Emma Court, B7a07063-0d3e-470e-9fce-f638a1998551

Eli Lilly Settlement Will Result In Cialis Patent Expiring As Early As 2018, Rather Than 2020

Eli Lilly & Co. said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly a year-and-a-half earlier than the patent was going to expire.
Tags: Finance, Article, FBN, Eli Lilly Co, Fbn/markets, MarketWatch Pulse, FOX BUSINESS/MARKETS, Emma Court, F3ce60f0-fd36-40bb-bcb5-066d895dafd5, Eli Lilly Settlement Will Result

Eli Lilly CFO Derica Rice To Retire At Year End

Eli Lilly & Co. said premarket Thursday that Chief Financial Officer Derica Rice will retire at the end of the year after working at the company for 27 years.
Tags: Finance, Article, FBN, Eli Lilly Co, Fbn/markets, MarketWatch Pulse, FOX BUSINESS/MARKETS, Emma Court, Derica Rice, 16787b0b-d642-4f6f-a6f3-c53767c96537, Eli Lilly CFO Derica

Written Description’s Shifting Focus to the Accused Embodiment

by Dennis Crouch Rivera v. ITC and Solofill (Fed. Cir. 2017) After conducting an investigation, a divided majority of commissioners of the USITC found no-violation of Adrian Rivera’s U.S. Patent No. 8,720,320 directed toward a re-usable K-cup that work with coffee pods. Investigation No. 337-TA-929.  In particular, the decision found all asserted claims invalid for lack of written description. On appeal, the Federal Circuit has affirmed — finding substantial evidence supported the Commission’s h...
Tags: Law, Itc, Patent, Fed, Rivera, Federal Circuit, ICU Medical, Eli Lilly Co, Written Description, USITC, Ariad Pharm Inc, Dennis Crouch Rivera, Solofill Fed, Adrian Rivera, Solofill, Alaris Medical System Fed

United Therapeutics reworks deal ahead of a key patent's expiration

Silver Spring drugmaker United Therapeutics Corp. extended an exclusive license with drug giant Eli Lilly & Co. to cover its pulmonary hypertension drug Adcirca, which will lose part of its patent protection later this year. The active ingredient in Adcirca is tadalafil, also the active pharmaceutical ingredient in Cialis, which is marketed by Eli Lilly (NYSE: LLY) to treat erectile dysfunction. United Therapeutics (NASDAQ: UTHR), in 2008, acquired the commercial rights to Adcirca from Eli Lill...
Tags: Eli Lilly, United Therapeutics, Eli Lilly Co, LLY, Eli Lilly NYSE, UTHR, United Therapeutics NASDAQ, United Therapeutics Corp, Adcirca

United States: CAFC's First Take On Divided Infringement For Method-Of-Treatment Claims - Haug Partners

On January 12, 2017, the Federal Circuit decided Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., providing its first opinion on divided infringement for pharmaceutical method patents unde
Tags: News, United States, Federal Circuit, Eli Lilly Co, Teva Parenteral Medicines Inc, Method Of Treatment Claims Haug Partners

Written Description, Disclosed Embodiments, and BRI

By Dennis Crouch The vast majority of written description problems arise when the patentee amends or adds claims with limitations not found in the original claim set and using language that does not directly map to specification disclosure.  In Cisco Systems v. Cirrex (Fed. Cir. 2017), the Federal Circuit provides an example of this in practice. [The Decision: Cisco] After the PTO initiated an inter partes reexamination, the patentee (Cirrex) dropped the original claims (1-34) and added new clai...
Tags: Post, Law, Cisco, Patent, Cisco Systems, Fed, PTO, The Board, Federal Circuit, Pierson, PLC, Dennis Crouch, Eli Lilly Co, PTAB, Gentry Gallery Inc, Berkline Corp